Table 1.
Patients and treatment characteristics.
| 5-FU-Based CT Treatment N = 95 |
Capecitabine-Based CT Treatment N = 62 |
p-Value | |||
|---|---|---|---|---|---|
| Characteristics | n | % | n | % | |
| Age (years), median (range) | 61 (38–90) | 67 (39–93) | 0.0048 | ||
| Sex Male Female |
17 78 |
17.89 82.11 |
10 52 |
16.13 83.87 |
0.8316 |
| ECOG performance status 0 1–2 |
91 4 |
95.79 4.21 |
57 5 |
91.94 8.06 |
0.3192 |
| History of pelvis/obstetric surgery Yes No/unknown |
49 46 |
51.58 48.42 |
25 37 |
40.32 59.68 |
0.1925 |
| T-classification 1–2 3 4 |
60 22 13 |
63.16 23.16 13.68 |
36 19 7 |
58.06 30.65 11.29 |
0.5583 |
| N-classification 0 1 2–3 |
41 21 33 |
43.16 22.10 34.74 |
31 12 19 |
50.00 19.35 30.65 |
0.7389 |
| HPV status Negative Positive Missing |
3 25 67 |
3.16 26.31 70.53 |
3 36 23 |
4.84 58.06 37.10 |
<0.001 |
| HIV status Negative Positive Missing |
21 2 72 |
22.10 2.11 75.79 |
29 2 31 |
46.77 3.23 50.00 |
0.0020 |
| SCC tumor marker Normal Elevated Unknown |
35 23 37 |
36.84 24.21 38.95 |
25 14 23 |
40.32 22.58 37.10 |
0.9342 |
| Radiation technique: boost-integrated Yes No |
86 9 |
90.53 9.47 |
57 5 |
91.94 8.06 |
1.0000 |
| Median RT treatment days (range) | 52 (46–78) | 52 (43–79) | 0.7949 | ||
| RT interruptions > 3 days Yes No |
17 78 |
17.89 82.11 |
8 54 |
12.90 87.10 |
0.5053 |
| Median duration of RT interruption (range), days | 6 (4–25) | 9.5 (5–20) | 0.0203 | ||
| Chemotherapy dose reduction Yes No |
38 57 |
40.00 60.00 |
28 34 |
45.16 54.84 |
0.6200 |
| Capecitabine or 5FU dose received <50% 50–75% 75–100% 100% |
1 12 25 57 |
1.05 12.63 26.32 60.00 |
6 10 12 34 |
9.68 16.13 19.35 54.84 |
0.0641 |